FTC challenges second settlement between Endo and Impax

Endo Pharmaceuticals abandoned its plans to re-enter the market for an opioid painkiller after concluding it would be more profitable to split monopoly profits with Impax Laboratories, the Federal Trade Commission has alleged.


Get unlimited access to all Global Competition Review content